NCT03793257

The EXCEL Registry of Patients Requiring ECMO

Recruiting now Last updated 15 September 2023

What this trial tests

trial in Critically Ill in 3,000 participants. Currently enrolling.

Timeline

1 February 2019

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Australian and New Zealand Intensive Care Research Centre
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	1 February 2019
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	29 locations across New Zealand, Australia

Conditions studied

• Critically Ill — all drugs for Critically Ill →
• Acute Respiratory Failure — all drugs for Acute Respiratory Failure →
• Acute Heart Failure — all drugs for Acute Heart Failure →
• Cardiac Arrest — all drugs for Cardiac Arrest →

Sponsor

Australian and New Zealand Intensive Care Research Centre — full company profile →

Who can join

18 and older, any sex, with Critically Ill or Acute Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ECMO is associated with significant costs, risks and requires specialist training and expertise. EXCEL is a novel, high-quality, detailed prospective registry of patients requiring ECMO in Australia and New Zealand. The registry provides information on patient selection, complications, costs and patient reported outcome measures. EXCEL uses the Theoretical Domains Framework to identify evidence-practice gaps and explore barriers and enablers to tailor implementation of evidence

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Incidence of death or disability at 6 months after extracorporeal membrane oxygenation in Australia: a prospective, multicentre, registry-embedded cohort study.
   Hodgson CL, Higgins AM, Bailey MJ, Anderson S, et al · · 2022 · cited 41× · PMID 36174613 · DOI 10.1016/s2213-2600(22)00248-x
2. International Consensus on Evidence Gaps and Research Opportunities in Extracorporeal Cardiopulmonary Resuscitation for Refractory Out-of-Hospital Cardiac Arrest: A Report From the National Heart, Lung, and Blood Institute Workshop.
   Morrison LJ, Hunt EA, Grunau B, Aufderheide TP, et al · · 2025 · cited 9× · PMID 40040619 · DOI 10.1161/jaha.124.036108
3. Hospital-level volume in extracorporeal membrane oxygenation cases and death or disability at 6 months.
   Ertugrul AD, Neto AS, Fulcher BJ, Charles-Nelson A, et al · · 2024 · cited 5× · PMID 39781494 · DOI 10.1016/j.ccrj.2024.08.006
4. Long-Term Functional Outcomes in the First 12 Months After VA-ECMO in Adult Patients: A Prospective, Multicenter Study.
   Serpa Neto A, Higgins AM, Bailey MJ, Anderson S, et al · · 2025 · cited 4× · PMID 40298907 · DOI 10.1161/circheartfailure.124.012476
5. Association of Respiratory Parameters at Venovenous Extracorporeal Membrane Oxygenation Liberation With Duration of Mechanical Ventilation and ICU Length of Stay: A Prospective Cohort Study.
   Thiara S, Serpa Neto A, Burrell AJC, Fulcher BJ, et al · · 2022 · cited 4× · PMID 35517643 · DOI 10.1097/cce.0000000000000689
6. Long-term outcomes of patients who received extracorporeal cardiopulmonary resuscitation (ECPR) following in-hospital cardiac arrest: Analysis of EXCEL registry data.
   Pound G, Jones D, Eastwood GM, Paul E, et al · · 2024 · cited 3× · PMID 39816674 · DOI 10.1016/j.ccrj.2024.08.008
7. Six-month outcomes following venovenous ECMO for severe COVID-19 and viral pneumonitis: 2019-2020 Australian experience.
   Burrell AJC, Neto AS, Udy A, Pellegrino V, et al · · 2022 · cited 1× · PMID 38046848 · DOI 10.51893/2022.1.oa10
8. Costs and complications of extracorporeal membrane oxygenation therapy in Australia and New Zealand.
   Wilcox KR, Meredith L, Burrell A, Fulcher B, et al · · 2026 · PMID 42163394 · DOI 10.1186/s13054-026-06086-7